Compass Pathways (CMPS) Stock Price

Compass Pathways Price

NASDAQ·CLOSED
13.77USD+0.44 (+3.25 %)
Market closed

The consensus 12-month price target for Compass Pathways is 20.40 USD, about 48.1% above where the stock trades today. Of 17 analysts, 15 rate the stock a buy — an overall Buy consensus. The stock trades about 212% above its 52-week low.

Compass Pathways stock price

Volume
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Compass Pathways over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Compass Pathways stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Compass Pathways's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Compass Pathways Stock Price History
DateCompass Pathways Price
8/24/202613.77 USD
8/21/202613.33 USD
8/20/202613.82 USD
8/19/202613.79 USD
8/18/202613.37 USD
8/14/202613.45 USD
8/13/202613.29 USD
8/12/202614.10 USD
8/10/202613.18 USD
8/7/202613.54 USD
8/6/202613.55 USD
8/5/202613.14 USD
8/4/202611.58 USD
8/3/202611.25 USD
7/31/202611.35 USD
7/30/202611.57 USD
7/29/202610.78 USD
7/27/202611.33 USD
7/23/202611.71 USD
7/22/202611.93 USD
7/21/202612.18 USD
7/20/202611.67 USD
7/17/202612.35 USD
7/16/202612.43 USD
7/15/202613.31 USD
7/14/202613.39 USD
7/13/202613.22 USD
7/10/202613.64 USD
7/9/202613.60 USD
7/8/202613.74 USD
7/7/202612.99 USD
7/6/202614.07 USD
7/2/202613.62 USD
7/1/202613.29 USD
6/30/202614.15 USD
6/29/202615.07 USD
6/26/202614.82 USD
6/25/202613.58 USD
6/24/202612.58 USD
6/23/202612.65 USD
6/22/202612.63 USD
6/18/202612.53 USD
6/17/202611.94 USD
6/16/202611.49 USD
6/15/202611.79 USD
6/12/202612.08 USD
6/11/202611.41 USD
6/10/202611.03 USD
6/5/202612.05 USD
6/4/202613.05 USD
6/3/202612.92 USD
6/2/202614.08 USD
6/1/202614.52 USD
5/29/202613.06 USD
5/28/202611.92 USD
5/27/202611.89 USD
5/26/202612.13 USD
5/22/202611.81 USD
5/21/202611.59 USD
5/20/202610.87 USD
5/19/202610.07 USD
5/13/202610.96 USD
5/12/20269.37 USD
5/8/20269.91 USD
5/7/20269.39 USD
5/5/20269.32 USD
5/4/20269.52 USD
5/1/20269.01 USD
4/30/20269.06 USD
4/29/20268.38 USD
4/28/20268.44 USD
4/27/20268.89 USD
4/24/20269.58 USD
4/23/20269.15 USD
4/22/20268.75 USD
4/21/20269.25 USD
4/20/20269.46 USD
4/17/20266.66 USD
4/16/20266.66 USD
4/15/20265.96 USD
4/14/20265.75 USD
4/13/20265.77 USD
4/10/20265.53 USD
4/9/20265.58 USD
4/8/20265.72 USD
4/7/20265.54 USD
4/6/20265.75 USD
4/2/20265.79 USD
4/1/20265.62 USD
3/31/20265.53 USD
3/30/20265.24 USD
3/27/20265.37 USD
3/26/20265.64 USD
3/25/20265.62 USD
3/24/20265.22 USD
3/23/20265.34 USD
3/20/20265.41 USD
3/19/20265.73 USD
3/18/20265.88 USD
3/17/20266.06 USD
3/16/20266.31 USD
3/13/20266.39 USD
3/12/20266.63 USD
3/11/20266.89 USD
3/10/20267.44 USD
3/9/20266.86 USD
3/6/20266.58 USD
3/5/20266.78 USD
3/4/20267.05 USD
3/3/20266.95 USD
3/2/20267.02 USD
2/27/20266.90 USD
2/26/20267.33 USD
2/25/20267.44 USD
2/24/20267.99 USD
2/23/20267.85 USD
2/20/20268.05 USD
2/19/20268.26 USD
2/18/20268.45 USD
2/17/20267.63 USD
2/13/20265.81 USD
2/12/20265.85 USD
2/11/20266.31 USD
2/10/20266.29 USD
2/9/20266.50 USD
2/6/20266.19 USD
2/5/20265.71 USD
2/4/20266.37 USD
2/3/20266.59 USD
2/2/20266.61 USD
1/30/20266.69 USD
1/29/20266.79 USD
1/28/20266.71 USD
1/27/20266.99 USD
1/26/20266.90 USD
1/23/20267.17 USD
1/22/20267.13 USD
1/21/20267.00 USD
1/20/20267.31 USD
1/16/20267.35 USD
1/15/20267.31 USD
1/14/20267.63 USD
1/13/20267.37 USD
1/12/20267.00 USD
1/9/20267.22 USD
1/8/20267.62 USD
1/7/20267.82 USD
1/6/20267.05 USD
1/5/20266.56 USD
1/2/20266.55 USD
12/31/20256.90 USD
12/30/20256.72 USD
12/29/20256.73 USD
12/26/20256.68 USD
12/24/20256.85 USD
12/23/20256.89 USD
12/22/20256.53 USD
12/19/20256.37 USD
12/18/20256.21 USD
12/17/20256.20 USD
12/16/20256.39 USD
12/15/20256.59 USD
12/12/20256.74 USD
12/11/20256.94 USD
12/10/20256.69 USD
12/9/20256.36 USD
12/8/20256.30 USD
12/5/20255.82 USD
12/4/20255.68 USD
12/3/20255.09 USD
12/2/20254.94 USD
12/1/20255.24 USD
11/28/20255.55 USD
11/26/20255.23 USD
11/25/20255.20 USD
11/24/20255.18 USD
11/21/20255.17 USD
11/20/20255.20 USD
11/19/20255.25 USD
11/18/20255.39 USD
11/17/20255.33 USD
11/14/20255.21 USD
11/13/20255.29 USD
11/12/20255.86 USD
11/11/20255.70 USD
11/10/20255.74 USD
11/7/20255.45 USD
11/6/20255.59 USD
11/5/20255.49 USD
11/4/20256.63 USD
11/3/20255.95 USD
10/31/20256.32 USD
10/30/20256.30 USD
10/29/20256.33 USD
10/28/20256.55 USD
10/27/20256.54 USD
10/24/20256.28 USD
10/23/20256.24 USD
10/22/20256.34 USD
10/21/20256.50 USD
10/20/20256.75 USD
10/17/20256.52 USD
10/16/20256.41 USD
10/15/20256.83 USD
10/14/20256.84 USD
10/13/20256.29 USD
10/10/20256.22 USD
10/9/20256.44 USD
10/8/20256.60 USD
10/7/20256.24 USD
10/6/20256.29 USD
10/3/20256.43 USD
10/2/20256.01 USD
10/1/20255.77 USD
9/30/20255.73 USD
9/29/20255.87 USD
9/26/20255.80 USD
9/25/20255.66 USD
9/24/20255.54 USD
9/23/20255.04 USD
9/22/20255.04 USD
9/19/20254.90 USD
9/18/20255.08 USD
9/17/20255.04 USD
9/16/20255.10 USD
9/15/20255.14 USD
9/12/20255.20 USD
9/11/20255.24 USD
9/10/20255.05 USD
9/9/20255.17 USD
9/8/20254.98 USD
9/5/20255.14 USD
9/4/20255.10 USD
9/3/20254.71 USD
9/2/20254.52 USD
8/29/20254.42 USD
8/28/20254.81 USD
8/27/20254.72 USD
Access this data via the Eulerpool API
Get Free API Key

Compass Pathways Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2023
0.00 USD
-136.92 M USD
-118.46 M USD
Jan 1, 2024
0.00 USD
-178.21 M USD
-155.12 M USD
Jan 1, 2025
0.00 USD
-179.04 M USD
-287.86 M USD
Jan 1, 2026 (e)
0.00 USD
-221.16 M USD
-162.08 M USD
Jan 1, 2027 (e)
39.70 M USD
-226.83 M USD
-162.68 M USD
Jan 1, 2028 (e)
230.71 M USD
-189.88 M USD
-28.26 M USD
Jan 1, 2029 (e)
495.87 M USD
91.16 M USD
66.71 M USD
Jan 1, 2030 (e)
821.12 M USD
381.41 M USD
255.27 M USD

Compass Pathways Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 26, 2026, 6:55 AM
 
REVENUEM USD
REVENUE GROWTH%
EBITM USD
EBIT MARGIN%
NET INCOMEM USD
NET INCOME GROWTH%
SHARESM
201820192020202120222023202420252026e2027e2028e2029e2030e
–––––––––39.00230.00495.00821.00
––––––––––489.74115.2265.86
-12.00-21.00-51.00-83.00-91.00-136.00-178.00-179.00-221.00-226.00-189.0091.00381.00
–––––––––-579.49-82.1718.3846.41
-13.00-19.00-60.00-71.00-91.00-118.00-155.00-287.00-162.00-162.00-28.0066.00255.00
–46.15215.7918.3328.1729.6731.3685.16-43.55–-82.72-335.71286.36
33.0021.7235.9341.8342.4461.9668.4793.6493.6493.6493.6493.6493.64
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Compass Pathways generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Compass Pathways retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Compass Pathways's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Compass Pathways has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Compass Pathways's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Compass Pathways stock margins

The Compass Pathways margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Compass Pathways. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Compass Pathways.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2021
0.00 %
- %
- %
Jan 1, 2022
0.00 %
- %
- %
Jan 1, 2023
0.00 %
- %
- %
Jan 1, 2024
0.00 %
- %
- %
Jan 1, 2025
0.00 %
- %
- %
Jan 1, 2026 (e)
0.00 %
- %
- %
Jan 1, 2027 (e)
0.00 %
-571.40 %
-409.79 %
Jan 1, 2028 (e)
0.00 %
-82.31 %
-12.25 %

Compass Pathways Stock Revenue, EBIT, Earnings per Share

The Compass Pathways earnings per share therefore indicates how much revenue Compass Pathways has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2021
0.00 USD
-1.99 USD
-1.71 USD
Jan 1, 2022
0.00 USD
-2.15 USD
-2.16 USD
Jan 1, 2023
0.00 USD
-2.21 USD
-1.91 USD
Jan 1, 2024
0.00 USD
-2.60 USD
-2.27 USD
Jan 1, 2025
0.00 USD
-1.91 USD
-3.07 USD
Jan 1, 2026 (e)
0.00 USD
-2.36 USD
-1.43 USD
Jan 1, 2027 (e)
0.35 USD
-2.42 USD
-1.43 USD
Jan 1, 2028 (e)
2.03 USD
-2.03 USD
-0.25 USD

Compass Pathways business model & stock analysis

Compass Pathways PLC is a leading company specializing in the development of groundbreaking therapies for the treatment of mental illnesses. The company was founded in 2016 and is headquartered in London. Its goal is to revolutionize the treatment of depression and other mental illnesses. The business model of Compass Pathways is based on researching psychedelics as a potential treatment for patients suffering from severe depression and anxiety disorders. The company uses innovative approaches to precisely study the effects of psychedelics on the human brain and develop new therapy concepts and products from that. An important area of Compass Pathways is clinical research. The company collaborates closely with leading research institutions to understand the impacts of psychedelics on the human brain. The research results are then used to develop innovative methods for therapeutic use of psychedelics. Another important area of Compass Pathways is the development of therapeutic products. The company has developed a patented process for producing psilocybin, a substance found in hallucinogenic mushrooms. This process achieves a very high purity of the substance, enabling precise dosing and better control of its effects. The flagship product of Compass Pathways is COMP360, a medication based on psilocybin that is being developed for the treatment of depression. The medication is currently in clinical Phase 2 trials, showing promising results. If COMP360 receives approval, it has the potential to drastically change the way we treat depression. Compass Pathways is also active in other areas. The company conducts a range of research projects related to various psychedelic substances, including LSD and other hallucinogens. Another important area of Compass Pathways is training therapists and other professionals in the use of psychedelic substances. The company offers relevant courses to promote understanding of the therapeutic use of psychedelics and enable their safe and effective application for patient treatment. Overall, Compass Pathways is a company focused on the development of groundbreaking therapies for mental illnesses. Through combining cutting-edge research, innovative products, and professional education, the company has the potential to revolutionize the way we treat mental illnesses.

Compass Pathways SWOT Analysis

Strengths

Compass Pathways PLC has several strengths that contribute to its success in the market. Firstly, the company is backed by significant funding, allowing it to invest in research and development and establish itself as a key player in the emerging field of mental health treatment. Secondly, Compass Pathways has a strong network of partnerships and collaborations with leading academic institutions and healthcare organizations, enabling access to valuable expertise and resources. Lastly, the company has patented technologies and intellectual property, giving it a competitive edge in the development and commercialization of innovative therapies.

Weaknesses

Despite its strengths, Compass Pathways PLC also faces certain weaknesses that could potentially hinder its growth. One of the major challenges is the high cost associated with the research and development of novel treatments, which may impact the company's profitability and ability to bring products to market in a timely manner. Additionally, as a relatively young company, Compass Pathways has limited brand recognition and market presence, which could pose obstacles in gaining traction and competing with established players in the industry.

Opportunities

The market offers numerous opportunities for Compass Pathways PLC to capitalize on. The growing awareness and acceptance of psychedelic-assisted therapies present a favorable environment for the company to position itself as a leader in this therapeutic field. Furthermore, the increasing prevalence of mental health disorders globally creates a significant demand for effective treatments, offering a vast market for Compass Pathways' innovative solutions. Moreover, strategic partnerships and collaborations with pharmaceutical companies and healthcare providers can help accelerate the development, commercialization, and distribution of the company's therapies.

Threats

Compass Pathways PLC faces several threats that could impact its business operations and market position. One prominent threat is the regulatory landscape and the potential for stringent regulations surrounding psychedelic-assisted therapies, which could limit market access and increase compliance costs. Additionally, competition within the mental health treatment industry is intensifying, and new entrants or existing players developing alternative therapies could erode Compass Pathways' market share. Moreover, there is a risk of unforeseen adverse events or negative public perception related to psychedelic treatments, which may lead to reputational damage and skepticism among key stakeholders.

Compass Pathways Employees

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Compass Pathways Employees
Details
Date
Compass Pathways Employees
Jan 1, 2020
- Employees
Jan 1, 2021
- Employees
Jan 1, 2022
- Employees
Jan 1, 2023
- Employees
Jan 1, 2024
- Employees
Jan 1, 2025
- Employees

Compass Pathways Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Compass Pathways historical P/E ratio, EBIT multiple, and P/S ratio

Compass Pathways annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Compass Pathways shares outstanding

The number of shares of Compass Pathways was 93.64 M in 2025. This indicates how many shares Compass Pathways is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2021
41.83 M Stocks
Jan 1, 2022
42.44 M Stocks
Jan 1, 2023
61.96 M Stocks
Jan 1, 2024
68.47 M Stocks
Jan 1, 2025
93.64 M Stocks
Jan 1, 2026 (e)
93.64 M Stocks
Jan 1, 2027 (e)
93.64 M Stocks
Jan 1, 2028 (e)
93.64 M Stocks

Current Compass Pathways forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
33.33 %
Buy
88.24 % (15)
Hold
11.76 % (2)
Sell
0.00 % (0)
12M Price Target
20.40
Last Price
13.77
Currency
USD
12M Return Potential
48.15 %
LTM Return
0 %

Compass Pathways Analyst Rating Actions

DateFirmActionRatingReliability
8/7/2026
HC Wainwright & Co.
HC Wainwright & Co.
MaintainedBuy–
8/6/2026
RBC Capital
RBC Capital
MaintainedOutperform48
8/6/2026
Morgan Stanley
Morgan Stanley
MaintainedOverweight51
8/6/2026
B. Riley Securities
B. Riley Securities
MaintainedBuy–
7/8/2026
Stifel
Stifel
MaintainedBuy56
7/8/2026
HC Wainwright & Co.
HC Wainwright & Co.
MaintainedBuy–
7/8/2026
Evercore ISI Group
Evercore ISI Group
UpgradeIn LineOutperform62
7/7/2026
Oppenheimer
Oppenheimer
MaintainedOutperform61
7/7/2026
Morgan Stanley
Morgan Stanley
MaintainedOverweight51
7/7/2026
BTIG
BTIG
MaintainedBuy–

Eulerpool Reliability Score (0–100): measures how often a firm’s bullish or bearish calls were directionally correct three months later, blended with the average return following its calls. Every rating we record is stored permanently and scores update continuously; firms with fewer than 3 measured calls are not scored yet.

Compass Pathways Earnings Estimates & Surprises

DateEPS estimateEPS ActualRevenue EstimatePrice reactionQuarterly report
7/29/2026-0.40USD-0.00USD-2026 Q2
5/13/2026-0.39USD-0.00USD-2026 Q1
2/25/2026-0.40USD-0.00USD-2025 Q4
5/6/2024-0.54USD-0.00USD-2024 Q1
2/5/2024-0.26USD-0.00USD-2023 Q4
11/3/2022-0.66USD-0.00USD-2022 Q3
8/4/2022-0.62USD-0.00USD-2022 Q2
5/10/2022-0.69USD-0.00USD-2022 Q1
2/24/2022-0.51USD-0.00USD-2021 Q4
11/9/2021-0.50USD-0.00USD-2021 Q3

Compass Pathways shareholder structure

% Name
10.71497%
DEEP TRACK CAPITAL, LP
DEEP TRACK CAPITAL, LP
9.42817%
RTW INVESTMENTS, LP
RTW INVESTMENTS, LP
5.59365%
BIT CAPITAL GMBH
BIT CAPITAL GMBH
4.40529%
TANG CAPITAL MANAGEMENT LLC
TANG CAPITAL MANAGEMENT LLC
3.93875%
TWO SIGMA INVESTMENTS, LP
TWO SIGMA INVESTMENTS, LP
3.81382%
MARSHALL WACE, LLP
MARSHALL WACE, LLP
...

Compass Pathways Beneficial Ownership Filings (SEC 13D/G)

Free Float
96.0%
Float Shares
-
Shares Outstanding
-
StakeHolderFiling
19.70%
ATAI Life Sciences BV
ATAI Life Sciences BV
SEC ↗
12.60%
Ekaterina Malievskaia
Ekaterina Malievskaia
SEC ↗
11.00%
Logos GP LLC
Logos GP LLC
SEC ↗
11.00%
Logos Global Master Fund LP
Logos Global Master Fund LP
SEC ↗
11.00%
Logos Global Management GP LLC
Logos Global Management GP LLC
SEC ↗
11.00%
contained in this form are not required to respond unless the form displays a currently valid OMB co
contained in this form are not required to respond unless the form displays a currently valid OMB co
SEC ↗
11.00%
Arsani William
Arsani William
SEC ↗
10.10%
ATAI Life Sciences AG
ATAI Life Sciences AG
SEC ↗
9.99%
Deep Track Capital, LP
Deep Track Capital, LP
SEC ↗
9.90%
RTW Investments, LP
RTW Investments, LP
SEC ↗

Compass Pathways Executives and Management Board

13 members · avg. age 65 · 31 % women

KN

Mr. Kabir Nath (60)

Chief Executive Officer, Executive Director · since 2022

4.34 M USD

Management

TL

Ms. Teri Loxam (53)

Chief Financial Officer

2.35 M USD
GG

Dr. Guy Goodwin (77)

Chief Medical Officer

1.48 M USD

Board of Directors

DN

Mr. David Norton (73)

Independent Director

411,562.00 USD
GS

Mr. Gino Santini (68)

Non-Executive Independent Chairman of the Board

410,440.00 USD
AJ

Dr. Annalisa Jenkins (59)

Independent Director

290,276.00 USD
RM

Dr. Robert McQuade (68)

Independent Director

282,790.00 USD
LM

Dr. Linda Mcgoldrick (70)

Independent Director

277,790.00 USD
DK

Ms. Daphne Karydas (52)

Independent Director

277,540.00 USD

Compass Pathways Supply Chain

Frequently asked questions about Compass Pathways

The business model of Compass Pathways PLC focuses on the development and commercialization of innovative therapies for mental health. As a leading mental health care company, Compass Pathways PLC is dedicated to improving the lives of patients suffering from treatment-resistant depression. It utilizes a patient-centered approach, conducting clinical trials to assess the efficacy and safety of its investigational treatment, psilocybin therapy. By partnering with healthcare providers, researchers, and regulatory bodies, Compass Pathways PLC aims to bring transformative mental health treatments to patients worldwide. With a strong commitment to scientific research and innovation, Compass Pathways PLC strives to address the significant unmet needs in mental health care.

Compass Pathways PLC primarily operates in the pharmaceutical and healthcare industry. As a leading mental health care company, Compass Pathways is dedicated to developing innovative therapies and advancing treatment options for patients with mental health disorders. With its focus on psilocybin therapy, the company aims to address the significant unmet needs in mental health through research, development, and collaboration with healthcare professionals. Compass Pathways PLC is committed to improving patient outcomes and transforming mental healthcare by providing effective and safe solutions for individuals living with mental health conditions.

The main competitors of Compass Pathways PLC in the market include companies such as MindMed Inc., Cybin Inc., and Atai Life Sciences AG.

Compass Pathways PLC is a renowned mental healthcare company specializing in the research and development of psychedelic therapies. Founded in 2016, the company aims to address the significant unmet need for effective, innovative treatments for mental health conditions such as depression. With a focus on psilocybin therapy, Compass Pathways PLC actively conducts clinical trials and collaborates with world-leading research institutions to advance psychedelic-assisted therapy. By leveraging their expertise and strategic partnerships, Compass Pathways PLC strives to revolutionize mental health care and deliver transformative solutions to patients worldwide.

Compass Pathways PLC, a renowned mental healthcare company, has achieved several significant milestones. Firstly, the company successfully obtained FDA breakthrough therapy designation for their psilocybin therapy, affirming its potential to address treatment-resistant depression. Secondly, they initiated the ground-breaking clinical trial, COMPASS Pathways, investigating the efficacy of psilocybin-assisted therapy for depression. Moreover, Compass Pathways PLC received a USD 24.4 million grant from the European Union's Horizon 2020 program, further supporting their research efforts. Additionally, the company went public on the NASDAQ stock exchange, symbol CMPS, raising substantial capital to propel their pioneering work. These achievements highlight Compass Pathways PLC's commitment to advancing mental health treatments and their growing prominence in the field.

Compass Pathways PLC, a leading mental healthcare company, is primarily present in the United States, United Kingdom, and Europe. With a global presence and a mission to develop innovative therapies, Compass Pathways PLC has established itself as a prominent player in the mental health treatment market. The company is specifically focused on developing psilocybin therapy, a potential breakthrough treatment for depression and other mental health disorders. With its strategic presence in key regions, Compass Pathways PLC aims to shape the future of mental healthcare worldwide.

Compass Pathways PLC represents a strong commitment to advancing mental health treatment. The company's corporate philosophy revolves around using innovation and rigorous scientific research to address the unmet needs in mental health care. Compass Pathways PLC places a high value on patients' well-being and aims to revolutionize the treatment of challenging mental health conditions like treatment-resistant depression through their breakthrough therapy, psilocybin. By emphasizing safety, efficacy, and patient-centric care, Compass Pathways PLC aspires to empower individuals suffering from mental health disorders and improve their quality of life.

Analysts currently set an average price target of 19.84 USD for the Compass Pathways stock (median: 20.40 USD), implying +44.1 % versus the latest price. The consensus is based on 17 analyst ratings.

Compass Pathways Analyst Price Targets 2026

17 analysts currently rate the Compass Pathways stock: 15 recommend buying, 2 holding and 0 selling.

Compass Pathways Analyst Price Targets 2026

Converted at the current exchange rate, the Compass Pathways share trades at 11.80 EUR (13.77 USD).

The Compass Pathways share (CMPS) is listed on 4 stock exchanges, including: NASDAQ (CMPS), Frankfurt (5Y6.F), München (5Y6.MU), Düsseldorf (5Y6.DU).

Compass Pathways PLC is a company specializing in the development of therapeutic psychedelic products. The English company was founded in 2016 and is headquartered in London. The business model of Compass Pathways PLC involves the research and development of psychoactive substances that are intended to be used in the treatment of mental illnesses. The company focuses particularly on the development of psilocybin, a compound found in mushrooms that affects the central nervous system and is known to induce hallucinations and altered perceptions. Compass Pathways is currently active in two different areas: research and clinical development. In research, the company is working on identifying new compounds and developing new methods of administering them. The key areas of focus are effectiveness, safety, and tolerability. In the context of clinical development, Compass Pathways is engaged in testing the effectiveness and tolerability of its products in clinical trials in order to obtain market approval. One of Compass Pathways' main products is psilocybin, which is administered in the form of capsules. These are intended to be used particularly in the treatment of depression and anxiety disorders. The aim is to enable patients to have a new experience of themselves and their environment in order to establish long-term changes in thinking and behavior patterns. The company collaborates closely with various research institutions and partners to advance psychedelic research and increase acceptance of these therapeutic options. Compass Pathways is also already cooperating with online therapy providers to enable a wider use of therapy products. As a business model, Compass Pathways aims to develop innovative and effective therapeutic options to improve the quality of life for patients with mental illnesses. The company works closely with various stakeholders in the healthcare sector and emphasizes networking to increase the likelihood of success. Overall, Compass Pathways' business model is characterized by a high degree of innovation and a special focus on the needs of patients. The focus on psychedelic substances and their therapeutic use makes the company a pioneer in this novel program area.

The revenue cannot currently be calculated for Compass Pathways.

The expected profit of Compass Pathways is -162.08 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Compass Pathways is currently -7.96. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Compass Pathways stock.

The P/S cannot be calculated for Compass Pathways currently.

The Eulerpool Quality Score for Compass Pathways is 2/10.

The ISIN of Compass Pathways is US20451W1018. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Compass Pathways is A2QCDR. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Compass Pathways is CMPS. The ticker symbol is used to trade Compass Pathways shares on the stock exchange.

Compass Pathways paid dividends every year for the past 0 years.

Compass Pathways is assigned to the 'Health' sector.

The dividends of Compass Pathways are distributed in USD.

All fundamentals and in-depth analysis of Compass Pathways

Our stock analysis for Compass Pathways stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Compass Pathways. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Compass Pathways Stock
Compass Pathways Revenue→
Compass Pathways Stock
Compass Pathways Net Income→
Compass Pathways Stock
Compass Pathways P/E→
Compass Pathways Stock
Compass Pathways P/S→
Compass Pathways Stock
Compass Pathways EBIT→
Compass Pathways Stock
Compass Pathways Dividend→
Compass Pathways Stock
Compass Pathways Directors Dealings→
Compass Pathways Stock
Compass Pathways Stocks→
Compass Pathways Stock
Compass Pathways Market capitalization→
Compass Pathways Stock
Compass Pathways Debt→
Compass Pathways Stock
Compass Pathways Liabilities→
Compass Pathways Stock
Compass Pathways Equity→
Compass Pathways Stock
Compass Pathways AAQS→
Compass Pathways Stock
Compass Pathways Employees→
Compass Pathways Stock
Compass Pathways ROE→
Compass Pathways Stock
Compass Pathways ROA→
Compass Pathways Stock
Compass Pathways ROCE→
Compass Pathways Stock
Compass Pathways News→
Compass Pathways Stock
Compass Pathways Analyst Price Targets→

Health Stocks

Compass TherapeuticsCommunity Health SystemsComprehensive Healthcare SystemsComera Life Sciences HoldingsCompugenColtene HoldingCompuMedColoplast A/SCompumedicsCollplant BiotechnologiesConavi MedicalCollegium PharmaceuticalAll Stocks A–Z →